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Summary 
T  cell hybridomas respond to activation  signals by undergoing  apoptotic cell death,  and this 
is likely to represent comparable events related to tolerance induction in immature and mature 
T  cells in vivo. Previous studies using antisense oligonucleotides implicated the c-Myc protein 
in the phenomenon  of activation-induced  apoptosis. This role for c-Myc in apoptosis is now 
confirmed in studies using a dominant negative form of its heterodimeric binding partner, Max, 
which we show here inhibits activation-induced apoptosis. Further, coexpression of a reciprocally 
mutant  Myc protein  capable of forming  functional  heterodimers  with  the  mutant  Max can 
compensate for the dominant  negative activity and restore activation-induced apoptosis. These 
results imply that Myc promotes activation-induced apoptosis by obligatory heterodimerization 
with  Max,  and therefore, by regulating  gene transcription. 
iT gation of the CD3 TCK complex on mature and imma- 
.LJ ture T  lymphocytes induces extensive gene expression, 
including the early induction of c-myc.  In immature T cells 
and T cell hybridomas this activation also leads to apoptotic 
cell death  in  a manner  which  is  dependent  upon  macro- 
molecular  synthesis  (1-4).  Previously,  we  used  antisense 
oligodeoxynucleotides to inhibit the expression of c-Myc in 
activated T hybridoma cells. This treatment leads to a rapid 
loss of c-Myc protein and we found that this blocked activation- 
induced apoptosis (5). This and other studies (6-9) have im- 
plicated c-Myc in some forms of apoptosis. Thus, in addition 
to promoting cell entry and passage through  the cell cycle, 
c-Myc functions  to direct cells into  an apoptotic pathway. 
The outcome of c-Myc activation is likely to depend upon 
other signals,  such as those provided by growth factors (7, 
8) or by other  oncogenes (6,  10-12). 
Myc is known to associate with  several proteins  within 
the cell,  including  the retinoblastoma  protein  (13),  TFII-I 
(14), and Max (15, 16). This last protein forms a heterodimer 
with Myc which regulates gene transcription by binding to 
specific DNA sequences (17-20). We therefore sought to de- 
termine whether the role of c-Myc in activation-induced apop- 
tosis was related to the functional activity of the Myc-Max 
heterodimer in control of gene expression.  To investigate this, 
we have used dominant negative mutants of c-Myc and Max 
which have been demonstrated to block transcriptional regu- 
lation  and  transformation  by c-Myc. 
Materials and Methods 
Plasmids, Cell Culture, and Transfections.  The ALl  T cell hy- 
bridoma has been previously described. Cells were maintained in 
IMDM supplemented with 5% FCS, 5  x  10 -S M fl-mercapto- 
ethanol, and 2 mM glutamine. The cells were transfected by elec- 
troporation using a capacitor-discharge pulse generator (GenePulser; 
Bio-Rad Laboratories, Richmond, CA). The cells were harvested 
from log phase cultures,  suspended in the original  conditioned 
medium at 10 x  106/ml and 0.8 ml cell suspension incubated for 
15 min on ice in the presence of 20 #g linearized plasmid. The 
suspensions were pulsed once with 250 V at 960-#F capacitance 
in a 0.4-mm gap cuvette, and pulsed cells were incubated a further 
15 min on ice, after which they were placed in 10 ml of fresh media. 
Transfected cell cultures were incubated for 24 h, washed, and then 
resuspended in fresh media. They were incubated  an additional 
10-14 d in the presence of selection media, containing either 800 
#g/ml G418 (GIBCO BRL, Gaithersburg,  MD) or 500 #g/ml 
hygromycin B (Sigma Chemical Co., St. Louis, MO). These bulk 
transfectants were reselected an additional  10 d in G418 or hy- 
gromycin before being used in the experiments described. Alterna- 
tively, individual clones were isolated by limiting dilution growth 
in the presence of selection antibiotics. The clones were screened 
for gene expression by reverse transcriptase-PCK (cDNA cycle; In- 
vitrogen,  San Diego,  CA) using  species- and construct-specific 
primers. All of the expression vectors containing the reciprocal ex- 
change mutants or wild-type myc and max genes used in this study 
were constructed and described by Amati et al. (21). Briefly, the 
myc exchange mutant (mycRX) was constructed by replacing the 
helix-loop-helix leucine zipper (HLH/LZ) domain of c-Myc with 
the complementary  domain from max.  Both c-myc and mycRX 
were placed in a G418-selectable  retroviral vector. The max exchange 
mutant (maxRX) and wild-type max were placed in a similar but 
hygromycin-selectable retroviral vector. All plasmids were gener- 
ously provided by Dr.  Bruno Amati  (Imperial Cancer  Research 
Fund,  London,  UK). All plasmids were linearized before trans- 
fections. 
Induction and Analysis of Apoptosis.  For the induction of apop- 
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Volume 180  December 1994  2413-2418 tosis, the AI.1 T hybridoma cells were cultured for 16 h in plates 
precoated with the monoclonal anti-CD3e antibody 145.2Cll (22) 
as previously described (2). For direct staining with propidium io- 
dide (PI) to assess viability, the contents of each of triplicate cul- 
ture wells were washed, resuspended in PBS containing 5/zg/ml 
PI, and analyzed  immediately using a FACScan  |  (log male) (Becton 
Dickinson & Co., Mountain View, CA). Dead cells  were identified 
as those taking up the dye. For analysis by DNA content, the cells 
were washed once in PBS/5 mM EDTA and then fixed in 70% 
ethanol for 30 min at room temperature. The fixed  cells  were washed 
once in PBS and resuspended in PBS containing 100 #g/ml RNase 
A/200 U/ml RNase T1. The cells were incubated 15-30 min at 
room temperature, after which they were stained by adding 1 vol 
PBS containing 100/zg/ml PI. The cells  were analyzed  by FACScan  | 
(linear scale) (Becton Dickinson  & Co.).  Apoptotic  cells were 
identified by having less than 2 n DNA content (i.e., sub-diploid). 
Cells were assessed for DNA fragmentation  in situ using a ter- 
minal deoxytransferase (TdT)-based nick end labeling assay which 
detects DNA strand breaks by using TdT to incorporate biotin- 
labeled UTP, which is subsequently detected by the addition of 
avidin-FITC (23). The cells were fixed in 1% formaldehyde/PBS, 
and stored in 70% ethanol. For UTP-biotin incorporation, the cells 
were resuspended in TdT buffer (0.2 M potassium cacodylate, 25 
mM Tris-HC1, pH 6.6, 2.5 mM cobalt chloride, 0.25 mg/ml BSA, 
100 U/ml TdT and 0.5 nM biotin-16-dUTP) and incubated for 30 
min at 37~  The cells were washed in PBS and resuspended in 
citrate/FITC-avidin buffer (0.6 M NaC1, 0.06 M NaCitrate,  2.5 
mg/ml fluoresceinated avidin, 0.1% Triton X-100, 5% (wt/vol) 
nonfat dry milk). The cells were either analyzed immediately or 
fixed in PBS/1% formaldehyde for later analysis. All FACS  |  data 
analysis was performed using LYSYS II software. For the quantita- 
tion of apoptosis by acridine orange/ethidium bromide, cells were 
collected from cultures stimulated with anti-CD3 and 100/~1 cell 
suspension immediately stained with 4/~1 of a cocktail of 100/zg/ml 
acridine orange and 100/~g/ml  ethidium bromide in PBS. Cells 
were scored as apoptotic/nonapoptotic  by UV light microscopy. 
Detection of Lymphokine Production.  II.,2  production was deter- 
mined by [3H]TdR uptake of the IL-2-responsive  cell line CTL.L 
(24) and quantitated  using a recombinant  IL-2 standard. 
Results and Discussion 
The strategy we used is illustrated in Fig.  1.  A  protein 
composed of Max with the HLH-LZ ofMyc (MaxRX) forms 
a nonfunctional dimer with endogenous Max in the cell (21). 
This MaxRX-Max  dimer  acts  as  an  inhibitor of normal 
Myc-Max heterodimer function in two ways: not only does 
MaxRX bind to and titrate out wild-type Max,  the tran- 
scriptionally inactive Max-MaxRX dimer can bind to DNA 
and prevent binding of wild-type Myc-Max dimers (21). A 
reciprocal mutation in Myc, i.e., MycRX, exchanges the HLH- 
LZ of Myc for that of Max. However, this molecule might 
have only limited inhibitory activity, since although MycRX 
can bind efficiently to wild-type Myc, the MycRX-Myc dimer 
is not predicted to bind efficiently to DNA (21).  However, 
when both the inhibitory MaxRX and the MycRX proteins 
are present, these will form a MycRX-MaxRX heterodimer 
that is functional. Studies by Amati et al. (21), upon which 
this strategy is based, showed that MycRX and MaxRX are 
both required for fibroblast transformation, neither one having 
transforming effects on its own. 
Constructs encoding the mutant  MaxRX  protein were 
transfected into A1.1 T hybridoma cells and clones with stable 
expression were selected.  Cells were then examined for their 
ability to undergo activation-induced apoptosis upon exposure 
to anti-CD3  antibody. As shown in  the four experiments 
in Fig. 2, expression of MaxRX significantly inhibited anti- 
CD3-induced  apoptosis,  as  determined by three different 
methods. In the first, cells were activated overnight and then 
stained with propidium iodide (without fixation) and ana- 
lyzed by FACS  |  (Fig.  2 A).  This simple method gives  an 
accurate assessment  of cell viability (since dead cells take up 
the dye [25]) but does not discriminate between apoptosis 
and necrosis.  Alternatively, cells were activated, fixed, and 
stained with propidium iodide to examine DNA content. 
When analyzed by FACS  |  apoptotic cells appear as a sub- 
Figure  1.  Schematic  representation 
of the Myc/Max  heterodimerization  do- 
main (HLH-LZ)  ~hange mutants used 
in this study and their relationships. 
Myc and Max form  transcriptionally  ac- 
tive heterodimers  through the interac- 
tion of HLH-LZ  motifs. MycRX  (21) 
was  generated by  reciprocally ex- 
changing the HLH-LZ  domain  of  wild- 
type Myc with that of wild-type  Max 
(RX for reciprocal  exchange,  Amati et 
al. [21]). MaxRX (21) was engineered 
by exchanging the HLH-LZ of wild- 
type  Max with that from  Myc. The di- 
agram shows the interaction of these 
two exchange  mutants, together  with 
their interactions with the wild-type 
proteins. MycRX forms dimers with 
both MaxRX  and with wild-type  Myc; 
however,  only  MycRX-MaxRX  dimers 
can bind DNA and are transcription- 
ally active. MaxR.X can form dimers 
with MycRX  or with wild-type  Max. 
Either dimer  may  bind DNA, but only 
the MycRX-MaxRX dimer is active. 
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Figure  2.  Inhibition of activation-induced  cell death  by the stable expression  of 
MaxRX. (A) Percentage of apoptotic cells after stimulation with monodonal antibody 
(2) measured by PI staining  of unfixed cells (A), or by fixation and staining with PI 
for assessment of DNA content (OI-q). Included is a determination of IL-2 produced 
after stimulation in one of the experiments (O). (B) Determination of DNA fragmen- 
tation by FACS  |  analysis of cells labded in situ with terminal deoxytransferase and 
UTP-biotin/avidin FITC after stimulation with anti-CD3. AI.1 maxRX transfectants 
were induced  to undergo apoptosis by overnight culture in anti-CD3 coated plates. 
Data shown for cell death as determined  by direct staining of unfixed cells (A) with 
PI represents  the mean of triplicate  cultures  with standard  deviation.  Bars represent 
the mean apoptosis of three  experiments,  with standard  deviation. 
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diploid population, owing to the fragmentation and subse- 
quent loss of the soluble DNA fragments (Fig. 2 A) (26). 
Finally, cells were analyzed using an in situ terminal deox- 
ytransferase  reaction to label 3'-OH  ends in the DNA,  a 
method that detects apoptosis involving DNA fragmenta- 
tion (23).  As shown in Fig.  2 B, a pronounced apoptotic 
peak was observed after activation of control cells, but not 
cells expressing MaxRX. This effect of MaxRX was not ob- 
served in the presence of MycRX. 
Our previous studies using c-myc  antisense  oligodeoxy- 
nucleotides indicated that inhibition of Myc expression in 
T hybridoma cells prevented activation-induced apoptosis but 
not activation-induced cytokine production (5). We there- 
fore examined cytokine production in the cells expressing 
MaxRX.  As shown in Fig.  2 A, cells expressing MaxRX 
produced a level of cytokine after activation that was equiva- 
lent  to  that  of the  other  cells, despite  significantly  less 
activation-induced apoptosis.  Thus,  the  function  of the 
Myc-Max heterodimer appears not to be important to the 
expression of IL-2 after activation. Analysis of the 5' flanking 
region of the IL-2 gene 2,300 bases upstream of the ATG 
start codon indicates the absence of a CACGTG consensus 
Myc-Max binding site. 
The use of cloned cell lines generated after transfection and 
selection carries the potential problem that any clone might 
gain or lose a function due to random factors not related to 
the transfected gene. An alternative approach is to examine 
the effects of expression of these proteins in bulk. Thus, cells 
were transfected  and selected,  and their response to activa- 
tion was examined without cloning. Results from several  bulk 
transfections are shown in Fig. 3. Again, we observed that 
expression of MaxRX inhibited activation-induced apoptosis 
while coexpression  of both MaxRX and MycRX did not. 
The effects of MycRX were inconsistent, but generally this 
molecule did not appear  to significantly inhibit the induc- 
tion of apoptosis. In one experiment we examined IL-2 produc- 
tion, and found equivalent levels of cytokine produced by 
cells expressing MaxRX, MycRX-MaxRX, and the control 
vectors, as above (results not shown). These results support 
those obtained using cloned cells above, and together, these 
demonstrate that in addition to Myc, the function of Max 
is required for activation-induced apoptosis.  The ability of 
MycRX to block the inhibitory effects of MaxRX strongly 
suggests that Myc and Max function as a heterodimer in 
activation-induced apoptosis. 
In these experiments we also examined possible effects of 
wild-type Max on activation-induced apoptosis in bulk trans- 
fected T hybridoma cells. Max is known to form homodimers 
(17, 18, 27, 28) and can inhibit the effects of the Myc-Max 
heterodimer in vivo (17, 20, 21, 29-31). As shown in Fig. 
3, wild-type Max similarly inhibited activation-induced apop- 
tosis. Thus, susceptibility to activation-induced apoptosis can 
apparently be regulated by the levels of Max in the cell, and 
this might therefore represent a potential control mechanism. 
Similarly, other proteins that influence the availability of Max 
(e.g.,  Mad [32]) might have roles in regulating activation- 
induced apoptosis. 
In a number of cell types, Myc expression can trigger apop- 
toffs (6-9) which is inhibited by growth factors (7, 8) or by 
the Bcl-2 protein (10-12). Most of these studies have involved 
the use of transfected cell lines. Recently, these observations 
were extended to group I Burkitt lymphoma cells which dis- 
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Figure 3.  Inhibition  of activation-induced apoptosis in bulk (un- 
cloned) transfected cells expressing Myc and Max exchange mutants. 
Percent cells undergoing apoptosis after stimulation with monoclonal 
antibody to the TCR-CD3 complex as determined by FACS  |  anal- 
ysis of DNA content in cells fixed and stained with PI (I-]AO), or 
by assessment of morphology and viability of cells in triplicate cul- 
tures stained with acridine orange/ethidium bromide, with standard 
deviation (@) (40). Bars represent the mean apoptosis of four experi- 
ments, with standard deviation. The induction and assessment of 
apoptosis by DNA content was as for Fig. 2 A. For the quantitation 
of apoptosis by acridine orange/ethidium bromide,  cells were col 
lected from cultures stimulated  with anti-CD3 and immediately  stained 
and scored by UV light microscopy. Data shown represents the mean 
of triplicate cultures with standard deviation. 
play a high incidence of apoptosis in vitro and in vivo. Inhi- 
bition  of c-Myc expression by IFN-o~ or c-myc antisense 
oligodeoxynucleotides  protected  these cells from apoptosis 
(33). Thus, c-Myc plays roles in apoptosis under a variety 
of conditions. 
Amati et al. (34) have provided evidence that Myc-induced 
apoptosis in fibroblasts depends upon the interaction of Myc 
and Max.  They used constructs encoding mutant proteins 
in which the residues forming electrostatic interactions within 
the leucine zipper heterodimerization motif  were reciprocally 
exchanged. Thus, the resulting MycEG protein does not bind 
to Max,  but does bind to a reciprocally modified MaxEG 
protein. When both are introduced into fibroblasts, the cells 
became highly susceptible to apoptosis. Thus, Myc induces 
apoptosis via interaction  with Max.  Our observations on 
activation-induced apoptosis are completely consistent with 
these findings. 
In contrast to the systems described here, apoptosis may 
occur due to a decrease in Myc expression in some cases. 
Thulasi  et al.  (35) noted that glucocorticoids  inhibit Myc 
expression in cells in which they induce apoptosis, and con- 
stitutive expression of Myc appears to protect these cells. Fur- 
ther, in a system partially related to the one described here, 
activation of the WEHI-231 B cell line via ligation of surface 
immunoglobulin induces apoptosis and a decrease in Myc ex- 
pression (36). Interestingly, c-myc-antisense  oligonucleotides 
were observed to stabilize expression of Myc in the activated 
B lymphomas and thereby prevent apoptosis. In support  of 
this contrasting role for Myc as an apparent survival signal 
in the transformed B cells, lines that resist activation-induced 
apoptosis fail to downregulate Myc upon activation (37). Thus, 
Myc appears to have strikingly different roles in the induc- 
tion versus prevention of apoptosis in different systems. 
The Myc-Max heterodimer functions as a transcriptional 
regulator to induce gene expression. Our results and those 
of Amati et al. (34) in which Myc-Max promotes apoptosis 
therefore suggest  that further transcription  is required for 
cell death, and thus Myc-Max-induced genes should be ex- 
amined for their potential roles in inducing apoptosis. One 
gene that is known to be induced by Myc is ornithine decar- 
boxylase (ODC) (38). Recently, Packham and Cleveland ex- 
amined the role of ODC in 32D cells, in which c-Myc ex- 
pression promotes IL-3 withdrawal-induced apoptosis. They 
found that expression of the ODC gene from a constitutive 
promoter rendered 32D cells susceptible to apoptosis in the 
absence of exogenous Myc (39). Further, they found that phar- 
macologic inhibition of ODC activity in Myc-expressing  cells 
reduced their susceptibility to apoptosis induction. Thus, at 
least one Myc-induced gene has been implicated in one form 
of apoptosis. 
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